There are very few sectors in the market where investors can have their cake and eat it too. That is, it’s not easy finding high growth, innovation and a sizable dividend. One of the few areas with all three can be found in the biotech sector. Our latest pick in the Best High Dividend Stocks Model Portfolio is a prime example!
Our pick is one of the sector’s elder statesmen and features a massive portfolio of blockbuster drugs. With a portfolio covering antivirals, HIV and oncology medicines, our pick throws off billions of dollars in cash flows and generates plenty of revenue. This supports its hefty 4.8% yield. Adding fuel to the fire has been smart M&A and a strong pipeline featuring more potential blockbuster medicines.
With continued innovation growth and demand for its medicines, our pick has the goods to keep rewarding shareholders for the long haul. With the stock going ex-dividend on Monday, June 14 (estimated date), it could be an optimal pick to add or increase your position in the stock.
To make room for this biotech stock, we had to remove a real estate firm from our list this week.
You can check out the Best High Dividend Stocks Model Portfolio to explore all the stocks.
